

Not for Retail distribution: this document is intended exclusively for Professional, Institutional, Qualified or Wholesale Investors / Clients, as defined by applicable local laws and regulation. Circulation must be restricted accordingly

# Euro Credit strategy

## ECB rates cut on the horizon


### What's happening?

- May was a month of two halves with rates rallying up to the 15th of May supported by reassuring data from the US. However, this move reversed in the second part of the month as we had another wave of volatility fueled by news about better growth momentum and the persistence of sticky core inflation - notably in services - leading to renewed concerns of delayed rate cycle cuts. The market is now pricing two and half cuts in the Eurozone and around one cut in the US this year. Indeed, economic data in the Eurozone has shown a pick-up in growth, strength in hiring and a modest improvement in industrial production. Hawkish German inflation was another case in point, bringing new risks of stickier inflation especially on services. The comment made by a US central banker about keeping the door open for a rate hike clearly did not help sentiment. The June cut is almost a done deal but there are increasing question marks regarding the pace of future cuts, especially if the Fed does not start its easing cycle. So, the June European Central Bank (ECB) speech will be key this time.
- In May, the euro credit market has performed relatively well although we have seen some signs of fatigue. Despite the volatility in the rates market, the ICE BofA Euro Credit index remained flat at 77bps. By sector, Financials subordinated debt and Corporate Hybrids were again the main outperformers tightening by 12bps and 6bps respectively. Retail, Healthcare and Consumers Goods underperformed the rest with a 3bps widening. On a name-by-name basis, high beta issuers like PBBGR, AARB, CPI, Aroundtown and Balder performed the best, while defensive credits as well as names that tapped the primary market, like Merck, Novo Nordisk, underperformed. In the senior bucket, financials (-3bps) performed well vs. corporates (+3bps) reflecting heavier supply in Non-Financials and still solid Q1 earnings season in the banking sector. The euro high-yield (HY) market has outperformed with a notable 19bps tightening during the month led by Real Estate (Adler, Heimstaden), Basics (Vallourec) and Media (Adebno and UPC).
- Primary issuance has been strong this month despite shorter weeks. Total issuance was at €84bn, split 35% for Financials and 55% for non-financials. Within corporates, we had few multi-tranches in the healthcare sector like Novo Nordisk, Medtronic and Johnson & Johnson. US issuers accounted for about 20% of the primary market issuers. Books were oversubscribed by 3.1x while new issue concession has been decreasing. Appetite for high beta remains intact (Bank of Ireland, WP Carey, Raiffeisen Bank and Alstom Hybrid oversubscribed 10x), while demand for most senior/low beta issuers is more mixed with books hardly more than 2.0x oversubscribed such as LVMH, Mercedes, Vinci and BMW. Despite this healthy primary, secondary spreads remain relatively resilient attesting still satisfactory fundamentals and more importantly robust credit market technicals. Indeed, flows continue to be solid into investment-grade (IG), and we saw some inflows into HY as well. In the HY, gross supply was at €14bn during the month. One of the big themes for IG supply in 2024 is that volumes were pulled forward in the first half of the year, which should result in relatively slower issuance in June onwards.

## Portfolio positioning and performance

- We have a **DTS above benchmark** at around 130% on average. We have an overweight position in spread duration versus benchmark.
- In **Financials**, we hold a positive outlook on the fundamental performance of European banks and we remain optimistic for the rest of 2024. Especially, we continue to be **overweight in Financial Subordinated** with a selective approach given tighter spreads.
- We have a preference for **Corporate Hybrids** compared to BB rated issuers, as they offer attractive carry and better risk-reward opportunities.
- In **Industrials**, we maintained our **overweight in Real Estate sector**, given the sector's attractive valuations and our focus on top-tier player in the Investment Grade universe.

### Asset Swap Spreads changes - MTD



Source: AXA IM, Bloomberg, as of 31/05/2024.  
ER00 = ICE BofA Euro Corporate Index


### Our Country Positioning

|                | UW | N | OW |
|----------------|----|---|----|
| Core           | ●  |   |    |
| Semi-Core      |    |   | ●  |
| Peripherals    |    |   | ●  |
| United States  | ●  |   |    |
| United Kingdom |    |   | ●  |

### Our Sector Positioning

|                        | UW | N | OW |
|------------------------|----|---|----|
| Financial Senior       |    |   | ●  |
| Financial Subordinated |    |   | ●  |
| Corporate Hybrids      |    |   | ●  |
| Defensive Senior       | ●  |   |    |
| Cyclical Senior        | ●  |   |    |

### Our targeted DTS is around 130%




No assurance can be given that the Euro Credit will be successful. Investors can lose some or all of their capital invested. The Euro Credit strategy is subject to risks including Credit risk, Liquidity risk, Derivatives and leverage, High yield debt securities, Contingent convertible bonds.

## Outlook

- The European Central Bank (ECB) has strongly hinted at its intention to initiate interest rate cuts in June. This indication comes at a time when the Eurozone inflation readings have come a long way since their all-time highs, providing the central bank with what it sees as a justification for taking action. Looking ahead, a potential complication may arise from the contrast between the longer-term policies of the Federal Reserve (Fed) and those of the Eurozone.
- In Credit, we believe the segment benefits from strong fundamentals and the ECB's clear willingness to normalize policy. The earnings season for the first quarter (Q1) of the year has been above expectations, both in the US and in Europe. And the technical have been very supportive with large inflows into the asset class. We continue to see valuations as attractive both in Investment Grade and in High Yield. Despite the tighter spread environment, we do not see any strong catalyst for spread widening and we focus on selectivity in issuer selection.

## Euro Credit Market Valuation



Source: AXA IM, Bloomberg, as of 31/05/2024. ER00 = ICE BofA Euro Corporate Index.

---

**Not for Retail distribution:** This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs.

This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.

The products or strategies discussed in this document may not be registered nor available in your jurisdiction. Please check the countries of registration with the asset manager, or on the web site <https://www.axa-im.com/en/registration-map>, where a fund registration map is available. Please note that the management company reserves the right, at any time, to no longer market the product(s) mentioned in this communication in an European Union country by notification to its authority of supervision in accordance with European passport rules.

In the event of dissatisfaction with the products or services, you have the right to make a complaint either with the marketer or directly with the management company (more information on our complaints policy available in English [here](#)). You also have the right to take legal or extra-judicial action at any time if you reside in one of the countries of the European Union. The European online dispute resolution platform allows you to enter a complaint form (by clicking [here](#)) and informs you, depending on your jurisdiction, about your means of redress (by clicking [here](#)).

Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

Issued by AXA INVESTMENT MANAGERS PARIS, a company incorporated under the laws of France, having its registered office located at Tour Majunga, 6 place de la Pyramide, 92800 Puteaux, registered with the Nanterre Trade and Companies Register under number 353 534 506, and a Portfolio Management Company, holder of AMF approval no. GP 92-08, issued on 7 April 1992. In other jurisdictions, this document is issued by AXA Investment Managers SA's affiliates in those countries.

In Hong Kong, this document is issued by AXA Investment Managers Asia Limited (SFC License No. AAP809), which is authorized and regulated by Securities and Futures Commission. This document is to be used only by persons defined as "professional investor" under Part 1 of Schedule 1 to the Securities and Futures Ordinance (SFO) and other regulations, rules, guidelines or circulars which reference "professional investor" as defined under Part 1 of Schedule 1 to the SFO. This document must not be relied upon by retail investors. Circulation must be restricted accordingly.

In Singapore, this document is issued by AXA Investment Managers Asia (Singapore) Ltd. (Registration No. 199001714W) and is intended for the use of Institutional Investors only as defined in Section 4A of the Securities and Futures Act (Cap. 289) and must not be relied upon by retail investors. Circulation must be restricted accordingly.

For Japanese clients: AXA Investment Managers Japan Ltd., whose registered office and principal place of business is at NBF Platinum Tower 14F 1-17-3 Shirokane, Minato-ku, Tokyo 108-0072, Japan, which is registered with the Financial Services Agency of Japan under the number KANTOZAIMUKYOKUCHO (KINSHO) 16, and is a member of Japan Securities Dealers Association, Type II Financial Instrument Firms Association, Investment Trust Association of Japan and Japan Investment Advisors Association to carry out the regulated activity of Financial Instrument Business under the Financial Instrument Exchange Law of Japan. In Japan, none of the funds mentioned in this document are registered under the Financial Instrument Exchange Law of Japan or Act on Investment Trusts and Investment Corporations. This document is purely for the information purpose for use by Qualified Institutional Investors defined by the Financial Instrument Exchange Law of Japan.

In Taiwan, this document is issued by AXA Investment Managers Asia Limited (SFC License No. AAP809), which is authorized and regulated by Securities and Futures Commission. This document and the information contained herein are intended for the use of professional or institutional investors and should not be relied upon by retail investors. They have been prepared and issued for private informational and educational purposes only at the sole request of the specified recipients, and not intended for general circulation. They are strictly confidential, and must not be reproduced, circulated, distributed, redistributed or otherwise used, in whole or in part, in any way without the prior written consent of AXA IM Asia. They are not intended for distribution to any persons or in any jurisdictions for which it is prohibited.

If any fund is highlighted in this communication (the “Fund”), its offering document or prospectus contains important information on selling restrictions and risk factors, you should read them carefully before entering into any transaction. It is your responsibility to be aware of and to observe all applicable laws and regulations of any relevant jurisdiction. AXA IM Asia does not intend to offer any Fund in any country where such offering is prohibited.

The offer, distribution, sale or re-sale of fund units/shares in Taiwan requires approval from and/or registration with Taiwanese regulatory authorities. To the extent that any units/shares of the Funds are not so licensed or registered, such units/shares are made available in Taiwan on a private placement basis only to banks, bills houses, trust enterprises, financial holding companies and other qualified entities or institutions (collectively, “Qualified Institutions”) and other entities and individuals meeting specific criteria (“Other Qualified Investors”) pursuant to the private placement provisions of the Rules Governing Offshore Funds. No other offer or sale of such units/shares in Taiwan is permitted. Taiwanese purchasers of such units/shares may not sell or otherwise dispose of their holdings except by redemption, transfer to a Qualified Institution or Other Qualified Investor, transfer by operation of law or other means approved by the Taiwan Financial Supervisory Commission.

For Malaysian investors: As the recognition by the Malaysian Securities Commission pursuant to Section 212 of the Malaysian Capital Markets and Services Act 2007 has not been / will not be obtained nor will this document be lodged or registered with the Malaysian Securities Commission, the shares referred to hereunder (if any) are not being and will not be deemed to be issued, made available, offered for subscription or purchase in Malaysia and neither this document nor any other document or other material in connection therewith should be distributed, caused to be distributed or circulated in Malaysia.

For Thailand investors: Nothing in this document shall constitute in any manner whatsoever a proposal to make available, offer for subscription or purchase or to issue an invitation to purchase or subscribe for any securities in Thailand or a proposal to implement any of the foregoing in Thailand nor has this document been approved by or registered with the Securities and Exchange Commission of Thailand (“SEC”). No person receiving a copy of this document may treat the same as constituting an invitation or offer to him in Thailand and such person shall not distribute or make available this document in Thailand. The issuer of this document shall not be liable in any manner whatsoever in the event this document is distributed or made available to any person in Thailand receiving a copy of this document. Since no application for approval has been or will be made to the SEC for the offering of the securities, or for the registration of this document, the securities shall not be offered for subscription or purchased or made available, whether directly or indirectly, in Thailand. It is the sole responsibility of recipients wishing to take any action upon this document to satisfy themselves as to the full observance of the laws of Thailand, to comply with all relevant government and regulatory approvals, and to comply with all applicable laws, including but not limited to exchange control laws.

For Investors in People’s Republic of China (PRC): This document does not constitute a public offer of the product., whether by sale or subscription in the PRC. The product is not being offered or sold directly or indirectly in the PRC to or for the benefit of, legal or natural persons of the PRC. Further, no legal or natural persons of the PRC may directly or indirectly purchase any of the product or any beneficial interest herein without obtaining all prior PRC’s governmental approvals that are required, whether statutorily or otherwise. Persons who come into possession of this document are required by the issuer and its representatives to observe these restrictions.

In Korea, AXA Investment Managers Asia (Singapore) Ltd is a registered Cross Border Investment Advisor/Discretionary Investment Management Company under the Financial Investment Services and Capital Markets Act (the “Act”). The activities referenced under the Act are 5-2-2 Investment Advisory Business and 6-2-2 Discretionary Investment Management Business, respectively. Its financial services are available in Korea only to Professional Investors within the meaning of Article 10 of Enforcement Decree of the Financial Investment Services and Capital Markets Act.

To the extent that any fund is mentioned in this document, neither the fund nor AXA IM Asia is making any representation with respect to the eligibility of any recipients of this document to acquire the units/shares in the fund under the laws of Korea, including but without limitation the Foreign Exchange Transaction Act and Regulations thereunder. The units/shares have not been registered under the Financial Investment Services and Capital Markets Act of Korea, and none of the units/shares may be offered, sold or delivered, or offered or sold to any person for re-offering or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to applicable laws and regulations of Korea.